Role Of Transcatheter Arterial Chemoembolization(TACE) After Hepatectomy In Hepatocellular Carcinoma

Hepatocellular carcinoma(HCC) is one of the most common cancers in the world,particularly prevalent in China,HCC is the third common cause of cancer death after cancer of the stomach and esophagus.Surgery is the only known curative option for hepatocellular carcinoma and the postoperative survival rate at 5-years can be 50%.But the postoperative recurrence rate of hepatocellular carcinoma at 5-years can be 60%and the postoperative recurrence rate of small hepatocellular carcinoma at 5-years can be 40%.The postoperative recurrence is one common cause of hepatocellular carcinoma death.To explore how to reduce the recurrent rate after hepatectomy is helpful.Transcatheter art erialchemo-embolization(TACE) is one of methods to prevent and treat the reccurnce of hepatocellular carcinoma.However,there are lots of debates about transcatheter art erialchemo-embolization.This study was designed to analyze the influence of postoperative transcatheter art erialchemo-embolization.1,To explore the indication of prophylactic transcatheter arterial chemoembolization(TACE) on postoperative recurrence of hepatocellular carcinomaObjective To evaluate the efficacy of prophylactic transcatheter arterial chemoembolization(TACE) on postoperative recurrence of hepatocellular carcinoma. Methods A retrospective analysis was performed on clinicopathologic data of 260 hepatocellular carcinoma patients who underwent curative hepatectomy in our hospital from Jan 2004 through Jun 2007.Of the 260 patients,104 underwent postoperative prophylactic TACE and others not.Results The overall survival rates at 1- and 2- years were respectively 84.1%and 70.5%.The overall disease-free survival rates at 1- and 2-years were respectively 69.2%and 58.4%.Of 260 overall patients,the disease-free survival rates at 1- and 2- years were respectively 72.8%and 54.9%in TACE group,and respectively 66.9%and 59.7%in non-TACE group,statistically significant difference of the cumulative disease-free survival rates at 1- and 2-years between TACE group and non-TACE group were not observed(P=0.145,0.405).Of 62 patients with tumor size＞or= 10 cm,the disease-free survival rates at 1- and 2-years were respectively 66.6%and 48.7%in TACE group,and respectively 44.6%and 31.2%in non-TACE group, statistically significant difference of the cumulative disease-free survival rates at 1- and 2- years between TACE group and non-TACE group were observed(P=0.025,0.025).Of 38 patients with vascular tumor thrombi,the disease-free survival rates at 1- and 2- years were respectively 33.0%and 0%in TACE group,and respectively 26.2%and 21.8%in non-TACE group,statistically significant difference of the cumulative disease-free survival rates at 1- years between TACE group and non-TACE group was observed(P=0.025),and not at 2- years(P=0.122).Conclusions Prophylactic TACE is preferred for hepatocellular carcinoma patients with high risk factors for recurrence such as tumor size＞or=10 cm and presented vascular tumor thrombi.2,Role of transcatheter arterial chemoembolization(TACE) on recurrent hepatocellular carcinomaObjective To evaluate the efficacy of transcatheter arterial chemoembolization(TACE) for recurrent hepatocellular carcinoma.Methods A retrospective analysis was performed on clinical data of 89 recurrent hepatocellular carcinoma patients who underwent curative hepatectomy in our hospital from Jan 2004 through Jun 2007.Of the 89 patients,66 underwent postoperative TACE and others not.Results The overall survival rates at 1- and 2-years were respectively 84.1%and 70.5%.The survival rates at 1- and 2-years were respectively 72.8%and 54.9%in TACE group,and respectively 66.9%and 59.7%in non-TACE group,statistically significant difference of the cumulative rates at 2-years between TACE group and non-TACE group were observed(P=0.046).Conclusions:TACE for recurrence of epatocellular carcinoma can be safely performed.